OBJECTIVE: To report the statistical analysis plan (first version) for the Balanced Solutions versus Saline in Intensive Care Study (BaSICS). METHODS: BaSICS is a multicenter factorial randomized controlled trial that will assess the effects of Plasma-Lyte 148 versus 0.9% saline as the fluid of choice in critically ill patients, as well as the effects of a slow (333mL/h) versus rapid (999mL/h) infusion speed during fluid challenges, on important patient outcomes. The fluid type will be blinded for investigators, patients and the analyses. No blinding will be possible for the infusion speed for the investigators, but all analyses will be kept blinded during the analysis procedure. RESULTS: BaSICS will have 90-day mortality as its primary endpoint, which will be tested using mixed-effects Cox proportional hazard models, considering sites as a random variable (frailty models) adjusted for age, organ dysfunction and admission type. Important secondary endpoints include renal replacement therapy up to 90 days, acute renal failure, organ dysfunction at days 3 and 7, and mechanical ventilation-free days within 28 days. CONCLUSION: This manuscript provides details on the first version of the statistical analysis plan for the BaSICS trial and will guide the study's analysis when follow-up is finished.
OBJECTIVE: To report the statistical analysis plan (first version) for the Balanced Solutions versus Saline in Intensive Care Study (BaSICS). METHODS: BaSICS is a multicenter factorial randomized controlled trial that will assess the effects of Plasma-Lyte 148 versus 0.9% saline as the fluid of choice in critically ill patients, as well as the effects of a slow (333mL/h) versus rapid (999mL/h) infusion speed during fluid challenges, on important patient outcomes. The fluid type will be blinded for investigators, patients and the analyses. No blinding will be possible for the infusion speed for the investigators, but all analyses will be kept blinded during the analysis procedure. RESULTS: BaSICS will have 90-day mortality as its primary endpoint, which will be tested using mixed-effects Cox proportional hazard models, considering sites as a random variable (frailty models) adjusted for age, organ dysfunction and admission type. Important secondary endpoints include renal replacement therapy up to 90 days, acute renal failure, organ dysfunction at days 3 and 7, and mechanical ventilation-free days within 28 days. CONCLUSION: This manuscript provides details on the first version of the statistical analysis plan for the BaSICS trial and will guide the study's analysis when follow-up is finished.
Authors: D G Altman; K F Schulz; D Moher; M Egger; F Davidoff; D Elbourne; P C Gøtzsche; T Lang Journal: Ann Intern Med Date: 2001-04-17 Impact factor: 25.391
Authors: Mervyn Singer; Clifford S Deutschman; Christopher Warren Seymour; Manu Shankar-Hari; Djillali Annane; Michael Bauer; Rinaldo Bellomo; Gordon R Bernard; Jean-Daniel Chiche; Craig M Coopersmith; Richard S Hotchkiss; Mitchell M Levy; John C Marshall; Greg S Martin; Steven M Opal; Gordon D Rubenfeld; Tom van der Poll; Jean-Louis Vincent; Derek C Angus Journal: JAMA Date: 2016-02-23 Impact factor: 56.272
Authors: J L Vincent; R Moreno; J Takala; S Willatts; A De Mendonça; H Bruining; C K Reinhart; P M Suter; L G Thijs Journal: Intensive Care Med Date: 1996-07 Impact factor: 17.440
Authors: Fernando G Zampieri; Lucas P Damiani; Jan Bakker; Gustavo A Ospina-Tascón; Ricardo Castro; Alexandre B Cavalcanti; Glenn Hernandez Journal: Am J Respir Crit Care Med Date: 2020-02-15 Impact factor: 21.405
Authors: Fernando G Zampieri; Luciano C P Azevedo; Thiago D Corrêa; Maicon Falavigna; Flavia R Machado; Murillo S C de Assunção; Suzana M A Lobo; Letícia K Dourado; Otavio Berwanger; John A Kellum; Nilton Brandão; Alexandre B Cavalcanti Journal: Crit Care Resusc Date: 2017-06 Impact factor: 2.159
Authors: Andrew D Shaw; Karthik Raghunathan; Fred W Peyerl; Sibyl H Munson; Scott M Paluszkiewicz; Carol R Schermer Journal: Intensive Care Med Date: 2014-10-08 Impact factor: 17.440
Authors: Fernando G Zampieri; Flávia R Machado; Rodrigo S Biondi; Flávio G R Freitas; Viviane C Veiga; Rodrigo C Figueiredo; Wilson J Lovato; Cristina P Amêndola; Ary Serpa-Neto; Jorge L R Paranhos; Marco A V Guedes; Eraldo A Lúcio; Lúcio C Oliveira-Júnior; Thiago C Lisboa; Fábio H Lacerda; Israel S Maia; Cintia M C Grion; Murillo S C Assunção; Airton L O Manoel; João M Silva-Junior; Péricles Duarte; Rafael M Soares; Tamiris A Miranda; Lucas M de Lima; Rodrigo M Gurgel; Denise M Paisani; Thiago D Corrêa; Luciano C P Azevedo; John A Kellum; Lucas P Damiani; Nilton Brandão da Silva; Alexandre B Cavalcanti Journal: JAMA Date: 2021-08-10 Impact factor: 56.272
Authors: Fernando G Zampieri; Flávia R Machado; Rodrigo S Biondi; Flávio G R Freitas; Viviane C Veiga; Rodrigo C Figueiredo; Wilson J Lovato; Cristina P Amêndola; Murillo S C Assunção; Ary Serpa-Neto; Jorge L R Paranhos; José Andrade; Michele M G Godoy; Edson Romano; Felipe Dal Pizzol; Emerson B Silva; Miqueias M L Silva; Miriam C V Machado; Luiz Marcelo S Malbouisson; Airton L O Manoel; Marlus M Thompson; Lanese M Figueiredo; Rafael M Soares; Tamiris A Miranda; Lucas M de Lima; Eliana V Santucci; Thiago D Corrêa; Luciano C P Azevedo; John A Kellum; Lucas P Damiani; Nilton B Silva; Alexandre B Cavalcanti Journal: JAMA Date: 2021-09-07 Impact factor: 56.272